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Evaluation of COVID-19 protease and HIV inhibitors 
interactions
The epidemic of the novel coronavirus disease 
(COVID-19) that started in 2019 has evoked an  urgent 
demand for finding new potential therapeutic 
agents. In this study, we performed a molecular 
docking of anti-HIV drugs to refine HIV protease 
inhibitors and nucleotide analogues to target 
 COVID-19. The evaluation was based on docking 
scores calculated by AutoDock Vina and top binding 
poses were analyzed. Our results suggested that 
lopinavir, darunavir, atazanavir, remdesivir, and 
tipranavir have the best binding affinity for the 
3-chymotrypsin-like protease of COVID-19. The 
comparison of the binding sites of three drugs, 
namely, darunavir, atazanavir and remdesivir, 
showed an overlap region of the protein pocket. 
Our study showed a strong affinity between 
 lopinavir, darunavir, atazanavir, tipranavir and 
COVID-19 protease. However, their efficacy should 
be confirmed by in vitro studies since there are 
concerns related to interference with their active 
sites.
Keywords: COVID-19, SARS-CoV-2, docking study, 
anti-HIV drugs, protease inhibitors
INTRODUCTION
COVID-19 is an RNA virus belonging to the Coronavirus family. Its sequence was 
analyzed and published briefly after its emergence (1). The viral genome encodes four 
non-structural proteins which are essential for the viral life cycle and one structural protein 
(spike glycoprotein) which is necessary for the infection of host cells. Therefore, the inhibi-
tion of these targets might be beneficial for the prevention of viral multiplication and trans-
mission. The COVID-19 sequence was found to be significantly similar to SARS-CoV and 
MERS-CoV which caused the outbreaks in 2002 and 2012, resp. (2). Therefore, there is an 
expectation that SARS-CoV or MERS-CoV medicines could be effective in preventing the 
spread of COVID-19.
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Despite a difference between COVID-19 and HIV genomes, successful treatment of 
COVID-19 with lopinavir/ritonavir; approved anti-HIV drugs, was recently reported (3, 4). 
This combination was also hypothesized to target a non-structural protein named 3-chymo-
trypsin-like (3CL) protease of SARS and MERS viruses and was associated with improved 
clinical outcomes in infected patients (1, 5, 6). Nucleoside reverse transcriptase (NRT), an 
enzyme that mediates replication of RNA viruses, has also been a major target for many 
antiviral drugs. Remdesivir is one of the nucleoside reverse transcriptase inhibitors (NRTI) 
that was used as a potential antiviral drug against a wide array of RNA viruses [including 
SARS/MERS-CoV, HIV, hepatitis B virus (HBV) or hepatitis C virus (HCV)] with promising 
results (6). Lopinavir/ritonavir [known as anti-protease inhibitors (PIs)] and remdesivir 
(known as an NRTI) were screened for COVID-19 treatment, or even for SARS-CoV or 
MERS-CoV at the early stage of the diseases. To provide more evidence for the possibility 
of COVID-19 treatment with anti-HIV drugs, this study was conducted to examine the 
binding affinity of the approved anti-HIV drugs and to evaluate the potential COVID-19 
drug candidates using computational approaches.
EXPERIMENTAL
Protein and ligands preparation
The 3CL protease structure (PDB ID: 6LU7), the main protease (Mpro) which plays an 
important role in the virus life cycle, was chosen as our target (7). We examined the FDA-
approved drugs of HIV PIs including atazanavir (atazanavir sulfate, ATV), darunavir (da-
runavir ethanolate, DRV), fosamprenavir (fosamprenavir calcium, FOS-APV, FPV), ritona-
vir (RTV), saquinavir (saquinavir mesylate, SQV), tipranavir (TPV) and lopinavir (8). 
Regarding the NRTIs, we have examined remdesivir, abacavir (abacavir sulfate, ABC), 
emtricitabine (FTC), lamivudine (3TC), tenofovir disoproxil fumarate (tenofovir DF, TDF) 
and zidovudine (azidothymidine, AZT, ZDV). These drugs were taken from the PubChem 
database (9) and then converted to three-dimensional structures using OpenBabel soft-
ware version 2.3.2. (10).
Docking investigation
All inhibitors were docked into the target protein using Autodock Vina version 1.1.2. 
(11). To optimize the results, the exhaustiveness of the global search was set as 400 whereas 
the maximum energy difference was selected. Ten binding modes of docking were generated 
with random starting positions of ligand, which have fully flexible torsion degrees of freedom. 
Positions of all atoms of the receptor were kept rigid. The center of grids was placed at the 
center of the mass of the receptor and the grid dimension was large enough (80 × 80 × 80 Å) 
to cover the entire 3CL-protease structure.
Docking results analysis
The docking results were evaluated by binding affinities and the interactions between 
protein and ligands as well as the favorable binding sites, which were likely to reproduce 
the experimental data and assess the precision of ligand preparation and docking method. 
Herein, we used N3 inhibitor (extracted from PDB 6LU7) as a positive control docking. To 
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obtain molecular insights into the 3CL protease binding site and the inhibition mecha-
nism, we analyzed the docking results of the top binding poses. A schematic diagram of 
networks of non-bonded contacts and hydrogen bonds between the ligands and protein 
binding site was prepared by LigPlot+ version 1.4.5 6. (12).
RESULTS AND DISCUSSION
The high binding affinity of PIs
The docking scores of all compounds are provided in Table I. Generally, PIs had a 
stronger binding affinity to 3CL protease than NRTIs. This finding indicates that PIs could 
Fig. 1. Binding interactions of lopinavir and tipranavir into 3CL protease.
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exhibit a stronger inhibitory activity than NRTIs. The top five binding scores were of lopi-
navir, darunavir, atazanavir, remdesivir, and tipranavir. In detail, the binding affinity of 
lopinavir was the highest (–9.2 kcal mol–1), followed by darunavir (–9.1 kcal mol–1), atazana-
vir (–8.9 kcal mol–1), remdesivir (–8.8 kcal mol–1) and tipranavir (–8.4 kcal mol–1).
Molecular interactions of COVID-19 protease and top binding inhibitors
The binding sites were highly sensitive to the targets. The binding sites of the top five 
inhibitors are shown in Fig. 1. It was observed that lopinavir and tipranavir had the same 
binding site, meanwhile, darunavir, atazanavir, remdesivir preferentially exposed another 
binding site similar to the docking control (N3 inhibitor). In the case of lopinavir inter-
action, the highest binding position is created by a hydrogen bond at Gln110 and several 
non-bonded contacts are Val104, Gln107, Asn151, Ser158, Val202, His246, Ile249, Phe294, 
Val297 and Pro293. Similar to lopinavir, the binding position of tipranavir was found by 
three hydrogen bonds including Gln110, Thr111 and Asp153, with the non-bonded contact 
network of Asn151, Ser158, Ile249, Pro293, Phe294, and Val297. For darunavir, atazanavir 
and remdesivir, we found an overlapped binding hotspot among the active site of 3CL 
protease, presented in Fig. 2. The common significant binding hotspot residues for daruna-
Table I. The binding affinity and in vitro results of candidate ligands to 3CL protease




Darunavir (darunavir ethanolate, DRV) –9.1 36.1 ± 1.2
Atazanavir (atazanavir sulfate, ATV) –8.9 60.7 ± 2.5
Tipranavir (TPV) –8.4 No inhibition (up to 200 µmol L–1)
Ritonavir (RTV) –8.2 13.7 ± 1.1
Fosamprenavir (fosamprenavir calcium, FOS-APV, FPV) –8.2 NA
Saquinavir (saquinavir mesylate, SQV) –7.9 31.4 ± 1.2
Control docking
N3 inhibitor –7.4 NA
Nucleoside reverse transcriptase inhibitors (NRTIs)
Remdesivir –8.8 NA
Abacavir (abacavir sulfate, ABC) –7.6 NA
Tenofovir Disoproxil Fumarate (tenofovir DF, TDF) –6.6 NA
Zidovudine (azidothymidine, AZT, ZDV) –6.5 NA
Emtricitabine (FTC) –6 NA
Lamivudine (3TC) –5.8 NA
NA – no activity
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vir, atazanavir, and remdesivir were as follows: His41, Met49, Leu141, Asn142, His164, 
Met165, Glu166, and Gln189. Atazanavir had no hydrogen bond, meanwhile, darunavir 
obtained a hydrogen bond with Ser46 and remdesivir created two hydrogen bonds with 
Thr45 and Gly143. Because the 3CL protease does not have a well-defined binding site, the 
top five inhibitors were located at different positions, as they preferred to interact closely 
to several hydrophobic residues.
DISCUSSION
Our results showed that some anti-HIV medicines had a strong affinity to 3CL protease 
of COVID-19 in silico model, including lopinavir, darunavir, atazanavir, remdesivir and 
tipranavir. These drugs show their effect by inhibition of HIV protease via blocking its 
active site, thus inhibiting the viral multiplication (8). Amongst them, the combination of 
lopinavir/ritonavir is being applied for COVID-19 treatment in China and showed positive 
recovery of patients, although the structure of HIV protease and COVID-19 are not exactly 
the same (13). The role of ritonavir is to inhibit cytochrome P450 (CYP) 3A4 resulting in 
slow elimination of lopinavir, which is strongly metabolized via CYP3A4, from the body. 
Therefore, lopinavir plays the main role in this combination for inhibition of viral matura-
Fig. 2. The overlap of binding positions of darunavir, atazanavir, and remdesivir into 3CL protease 
at the active site.
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tion. In our study, the strong affinity between lopinavir and 3CL protease might elucidate 
its effect; this finding was in line with the previous study (14). The chemical structure of 
lopinavir appeared to be fixed inside the viral protein that could cause strong binding as 
well as the long-term interaction between them. However, there was a concern relating to 
its ability to reduce viral replication when tested on MERS-CoV. This combination appeared 
to improve the symptoms rather than kill the virus. Its pharmacokinetic characteristics 
revealed binding of the majority of lopinavir to plasma proteins, which means that only a 
minor free unbound level of the drug is available to exert its effect. Fortunately, the in vitro 
maximal effective concentration (EC50) against MERS-CoV of this treatment was within the 
average level of the free drug in the body. Until now, the current reports indicated that the 
symptoms of COVID-19 patients have improved but there is no report of viral elimination 
relating to this treatment (15, 16). A recent in vitro study reported that the IC50 value of  lopinavir 
in inhibiting protease was about 500 μmol L–1 (17). Taking all together, we recommend 
screening of other NRTIs with good bioavailability and high levels of the free active form 
in the body.
Our findings were in line with another study that used another in silico model about 
the potency of atazanavir (18). This study showed that atazanavir might be the best candi-
date, as it had the highest inhibitory potency amongst the tested structures. The inhibitory 
potency values in this prediction model could not exactly reflect the potency of a drug in 
clinical practice, as the efficacy of lopinavir/ritonavir was predicted to be weak. However, 
due to the consistency in prediction between the two studies, atazanavir could become a 
potential candidate in screening for new COVID-19 medicines. This drug also has satis-
factory pharmacokinetic characteristics, with modest bioavailability and a high percent of 
unchanged form in the body (19). On the other hand, a previous screening reported that 
atazanavir was ineffective for the treatment of MERS-CoV; therefore, in vitro or in vivo 
studies should be conducted to examine its efficacy before applying it into clinical practi-
ces (16).
Darunavir had a stronger affinity to 3CL protease than atazanavir, but its pharmaco-
kinetic characteristics are not very prominent, as it shows fast absorption with fast distri-
bution and elimination as well (20). The percentage of its free form level is also quite small, 
similar to lopinavir. Therefore, we cannot ensure whether it could reach the feasible con-
centration required to exert its effect. It is worthy to mention that a previous in vitro study 
conducted by Mahdi et al. (21) reported that lopinavir, ritonavir, darunavir, saquinavir and 
atazanavir were able to inhibit SARS-CoV-2 main viral protease in the cell culture, albeit 
in concentrations much higher than their achievable plasma levels. They stated that inhi-
bition by lopinavir was attributed to its cytotoxicity, while ritonavir was the most effective 
of the panel, with IC50 of 13.7 μmol L–1. On the other hand, atazanavir was the only PI to 
inhibit the viral protease both in cell culture and in in vitro enzymatic assay.
Despite our findings could suggest potential candidates that had a strong binding 
affinity to 3CL protease, being potential agents against SARS-CoV-2, we recommend all 
compounds (even those that had a weaker affinity to 3CL protease) to be tested, at least in 
vitro, to affirm their activity (22–24). A virtual screening study has identified 14 known 
antiviral drugs with possible inhibitory effects on the main protease of SARS-CoV-2 (24). 
Moreover, besides 3CL protease, other proteinases could become targets for screening 
agents against SAR-CoV-2. These targets are papain-like protease, helicase, RNA-depen-
dent RNA polymerase, and spike glycoprotein (1). Therefore, we recommend further stu-
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dies to determine the interaction of other candidates and the mentioned targets in order to 
find out potential drugs.
For instance, remdesivir has a lower affinity to 3CL proteinase compared to lopinavir, 
darunavir or atazanavir, but it has a good effect in clinical practice because it is active 
through its inhibition of reverse transcriptase, rather than viral proteinase such as 3CL 
proteinase.
CONCLUSIONS
In our work, five anti-HIV inhibitors, namely, lopinavir, darunavir, atazanavir, remde-
sivir, and tipranavir were identified to have potential inhibitory activities against COVID-19 
protease. A set of possible top hits binding interactions between 3CL protease and anti-HIV 
drugs could substantially contribute to the rational drug development against COVID-19.
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